AlloVir to combine with Kalaris Therapeutics in all-stock transaction
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 08 2024
0mins
Should l Buy ?
Merger Agreement: AlloVir has entered into a definitive all-stock merger agreement with Kalaris Therapeutics, where AlloVir will acquire 100% of Kalaris' outstanding equity. Post-merger, AlloVir stockholders will own approximately 25.05% and Kalaris stockholders about 74.95% of the combined entity.
Financial Outlook: The merged company is expected to have around $100 million in cash to support operations until late 2026, will operate under the name Kalaris Therapeutics, and plans to trade on Nasdaq as "KLRS." The merger is anticipated to close in Q1 2025, pending necessary approvals and conditions.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
